Da Tang1, Guang Fu1, Wenbo Li2, Ping Sun3, Patricia A Loughran4, Meihong Deng5, Melanie J Scott4,6,7, Timothy R Billiar8,9,10. 1. Department of General Surgery, The Third Xiangya Hospital, Central South University, 410000, Changsha, People's Republic of China. 2. Department of Burn and Plastic Surgery, The Second Xiangya Hospital, Central South University, 410000, Changsha, People's Republic of China. 3. Department of Hepatobiliary Surgery, Union Hospital, Huazhong University of Science and Technology, Wuhan, People's Republic of China. 4. Department of Surgery, University of Pittsburgh, PA, 15213, Pittsburgh, USA. 5. Department of Surgery, Ohio State University Medical School, OH, Columbus, USA. 6. Pittsburgh Trauma Research Center, University of Pittsburgh, 15213, Pittsburgh, PA, USA. 7. Pittsburgh Liver Research Center, University of Pittsburgh, 15213, Pittsburgh, PA, USA. 8. Department of Surgery, University of Pittsburgh, PA, 15213, Pittsburgh, USA. billiartr@upmc.edu. 9. Pittsburgh Trauma Research Center, University of Pittsburgh, 15213, Pittsburgh, PA, USA. billiartr@upmc.edu. 10. Pittsburgh Liver Research Center, University of Pittsburgh, 15213, Pittsburgh, PA, USA. billiartr@upmc.edu.
Abstract
BACKGROUND: Hepatic ischemia/reperfusion (I/R) injury can be a major complication following liver surgery contributing to post-operative liver dysfunction. Maresin 1 (MaR1), a pro-resolving lipid mediator, has been shown to suppress I/R injury. However, the mechanisms that account for the protective effects of MaR1 in I/R injury remain unknown. METHODS: WT (C57BL/6J) mice were subjected to partial hepatic warm ischemia for 60mins followed by reperfusion. Mice were treated with MaR1 (5-20 ng/mouse), Boc2 (Lipoxin A4 receptor antagonist), LY294002 (Akt inhibitor) or corresponding controls just prior to liver I/R or at the beginning of reperfusion. Blood and liver samples were collected at 6 h post-reperfusion. Serum aminotransferase, histopathologic changes, inflammatory cytokines, and oxidative stress were analyzed to evaluate liver injury. Signaling pathways were also investigated in vitro using primary mouse hepatocyte (HC) cultures to identify underlying mechanisms for MaR1 in liver I/R injury. RESULTS: MaR1 treatment significantly reduced ALT and AST levels, diminished necrotic areas, suppressed inflammatory responses, attenuated oxidative stress and decreased hepatocyte apoptosis in liver after I/R. Akt signaling was significantly increased in the MaR1-treated liver I/R group compared with controls. The protective effect of MaR1 was abrogated by pretreatment with Boc2, which together with MaR1-induced Akt activation. MaR1-mediated liver protection was reversed by inhibition of Akt. CONCLUSIONS: MaR1 protects the liver against hepatic I/R injury via an ALXR/Akt signaling pathway. MaR1 may represent a novel therapeutic agent to mitigate the detrimental effects of I/R-induced liver injury.
BACKGROUND:Hepatic ischemia/reperfusion (I/R) injury can be a major complication following liver surgery contributing to post-operative liver dysfunction. Maresin 1 (MaR1), a pro-resolving lipid mediator, has been shown to suppress I/R injury. However, the mechanisms that account for the protective effects of MaR1 in I/R injury remain unknown. METHODS: WT (C57BL/6J) mice were subjected to partial hepatic warm ischemia for 60mins followed by reperfusion. Mice were treated with MaR1 (5-20 ng/mouse), Boc2 (Lipoxin A4 receptor antagonist), LY294002 (Akt inhibitor) or corresponding controls just prior to liver I/R or at the beginning of reperfusion. Blood and liver samples were collected at 6 h post-reperfusion. Serum aminotransferase, histopathologic changes, inflammatory cytokines, and oxidative stress were analyzed to evaluate liver injury. Signaling pathways were also investigated in vitro using primary mousehepatocyte (HC) cultures to identify underlying mechanisms for MaR1 in liver I/R injury. RESULTS:MaR1 treatment significantly reduced ALT and AST levels, diminished necrotic areas, suppressed inflammatory responses, attenuated oxidative stress and decreased hepatocyte apoptosis in liver after I/R. Akt signaling was significantly increased in the MaR1-treated liver I/R group compared with controls. The protective effect of MaR1 was abrogated by pretreatment with Boc2, which together with MaR1-induced Akt activation. MaR1-mediated liver protection was reversed by inhibition of Akt. CONCLUSIONS:MaR1 protects the liver against hepatic I/R injury via an ALXR/Akt signaling pathway. MaR1 may represent a novel therapeutic agent to mitigate the detrimental effects of I/R-induced liver injury.
Authors: Wayel Jassem; Emmanuel Xystrakis; Yasmeen G Ghnewa; Muhammed Yuksel; Oltin Pop; Marc Martinez-Llordella; Yamen Jabri; Xiaohong Huang; Juan J Lozano; Alberto Quaglia; Alberto Sanchez-Fueyo; Constantin C Coussios; Mohamed Rela; Peter Friend; Nigel Heaton; Yun Ma Journal: Hepatology Date: 2019-03-13 Impact factor: 17.425
Authors: Hai Huang; Gary W Nace; Kerry-Ann McDonald; Sheng Tai; John R Klune; Brian R Rosborough; Qing Ding; Patricia Loughran; Xiaorong Zhu; Donna Beer-Stolz; Eugene B Chang; Timothy Billiar; Allan Tsung Journal: Hepatology Date: 2014-04-01 Impact factor: 17.425
Authors: Gonzalo Soto; María José Rodríguez; Roberto Fuentealba; Adriana V Treuer; Iván Castillo; Daniel R González; Jessica Zúñiga-Hernández Journal: Int J Mol Sci Date: 2020-01-15 Impact factor: 5.923
Authors: María José Rodríguez; Matías Sabaj; Gerardo Tolosa; Francisca Herrera Vielma; María José Zúñiga; Daniel R González; Jessica Zúñiga-Hernández Journal: Cells Date: 2021-12-03 Impact factor: 6.600